About
Nayacure Labs is a regenerative medicine company developing technologies to restore the function of failing body parts and enhance human health. Nayacure is building a pipeline of therapeutic assets and product candidates to address a range of diseases: artificial clot for localized drug delivery (based on the natural ability of drugs to bind to plasma proteins), organs on demand, and a placental stem cell therapy for neurodegeneration. Nayacure's lead program is in developing personalized organs in an effort to make more organs available for transplantation and substantially reduce the need for immunosuppressant drugs following organ transplantation. Nayacure's goal is to cross the immunological barrier to xenotransplantation, providing an unlimited source of humanized organs and treating human-derived composite allografts (e.g. extremities, face, and womb) to reduce their immunogenic burden and make them tolerable.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Nayacure Labs' primary focus in regenerative medicine?
- Nayacure Labs is focused on developing technologies to restore the function of failing body parts and enhance human health, with a lead program in personalized organs for transplantation.
- When was Nayacure Labs founded?
- Nayacure Labs was founded in December 2010.
- Where is Nayacure Labs headquartered?
- Nayacure Labs is headquartered in Zikhron Ya'akov, Israel.
- What is Nayacure Labs' current funding stage?
- Nayacure Labs is currently in the Pre-Funding stage.
- What is Nayacure Labs' primary sector classification?
- Nayacure Labs' primary sector classification is Health Tech & Life Sciences.
- Who is a founder of Nayacure Labs?
- Shahar Cohen, MD, is a founder of Nayacure Labs.
- What is one of the therapeutic assets Nayacure Labs is developing?
- Nayacure Labs is developing an artificial clot for localized drug delivery.
- What is Nayacure Labs' goal regarding xenotransplantation?
- Nayacure Labs' goal is to cross the immunological barrier to xenotransplantation, aiming to provide an unlimited source of humanized organs.